Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours Β· Estimated delivery Aug 19 - Aug 24
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes
In contrast, short-acting formulations such as exenatide and the older-generation agent lixisenatide are now prescribed far less frequently, and several formulations have been withdrawn from the market in certain countries, largely due to limited clinical uptake, the availability of more effective long-acting alternatives, and commercial considerations rather than confirmed safety concerns
Cost and insurance coverage newer drugs can be harder to access
Apex Peptides NCBI PubMed Metaanalysis on Retatrutide receptor agonist effects Peerreviewed reference documenting mechanistic insights into multireceptor engagement
US$ 27.87
US$ 21.27
US$ 20.89
US$ 25.62
US$ 23.44
US$ 21.47
US$ 28.78
US$ 25.57
US$ 29.39
